Axsome Therapeutics Priced, Nasdaq: AXSM

Developing novel therapies for pain and CNS disorders utilizing the 505(b)(2) pathway.

Industry: Health Care

Latest Trade: $5.80 0.00 (0.0%)

First Day Return: -2.9%

Return from IPO: -35.6%

Industry: Health Care

We are a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system, or CNS, disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our product candidate portfolio includes two late-stage candidates, AXS-02 and AXS-05, which we are developing for multiple indications. We recently initiated a Phase 3 trial with AXS-02 in complex regional pain syndrome, or CRPS, and plan to initiate a Phase 3 trial in knee osteoarthritis associated with bone marrow lesions in or before the first quarter of 2016 pursuant to a Special Protocol Assessment, or SPA. We also plan to initiate a Phase 3 trial with AXS-05 in treatment resistant depression in or before the first quarter of 2016. We aim to become a fully integrated biopharmaceutical company that develops and commercializes differentiated therapies that expand the treatment options available to caregivers and improve the lives of patients living with pain and other CNS disorders.
more less
IPO News for Axsome Therapeutics
more
IPO Data
IPO File Date 10/13/2015
Offer Price $9.00
Price Range $11.00 - $13.00
Offer Shares (mm) 5.7
Deal Size ($mm) $51
IPO Data
IPO Date 11/19/2015
Offer Price $9.00
Price Range $11.00 - $13.00
Offer Shares (mm) 5.7
Deal Size ($mm) $51
Underwriters
more
Company Data
Headquarters New York, NY
Founded 2012
Employees 9
Website www.axsome.com